| Document |
Document Title |
|
WO/2017/154938A1 |
[Problem] The purpose of the present invention is to provide a method for uniformly and efficiently producing a sugar having a sulfate group and/or phosphate group in the molecule or a compound containing the sugar. [Solution] The presen...
|
|
WO/2017/156380A1 |
This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.
|
|
WO/2017/143453A1 |
This disclosure provides methods and strategies for inhibiting the growth of TP53 wild-type cancer cells, comprising contacting the cell with 2',2'-difluoro-5-aza-2'- deoxycytidine or a 2',2'-difluoro-5-aza-2'-deoxycytidine prodrug. Also...
|
|
WO/2017/145151A1 |
Disclosed herein is a process for preparing nicotinamide riboside (NR) from an NR precursor and a phosphate-binding agent in a solvent. The reaction-derived mixture comprising NR may be further used without further processing in a variet...
|
|
WO/2017/144423A1 |
The present invention relates to a process for the synthesis of Sofosbuvir of formula (I) comprising the selective mono-deacetylation reaction of a compound of formula (V) to obtain a compound of formula (IV).
|
|
WO/2017/143113A1 |
The present invention is directed to methods for the use of 5 '-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus- related diseases or conditions, eye disorders, cancer, or di...
|
|
WO/2017/142984A1 |
The application provides methods for treatment or prophylaxis of Zika Virus mediated diseases with compounds of Formula I, wherein the variables R1, R2, R3, R4, R5, and Base are defined as described hereinabove.
|
|
WO/2017/142913A1 |
A method for making a polynucleotide is provided that includes (a) delivering one or more reaction reagents including an error prone or template independent DNA polymerase, cations and a selected nucleotide to a reaction site including a...
|
|
WO/2017/142054A1 |
Provided is an artificial nucleoside or an artificial nucleotide which can constitute an artificial oligonucleotide having excellent nuclease resistance. An artificial nucleoside or an artificial nucleotide, which is a compound represent...
|
|
WO/2017/137374A1 |
The present invention concerns methods and approaches for modifying guanosine tetraphosphate (ppGpp) homeostasis in photosynthetic eukaryotes, in particular plants or algae, in order to modulate senescence for the remobilisation of nitro...
|
|
WO/2017/124315A1 |
A method for enzymatic preparation of fludarabine phosphate, comprising reaction of fludarabine with a high-energy phosphate compound under the action of deoxyribonucleic acid kinase. According to said method, acetate kinase and acetyl p...
|
|
WO/2017/127357A1 |
A DNA aptamer is provided that binds to a cholecystokinin B receptor (CCBKR), allowing for delivery of therapeutic agents or imaging agents to cells having the CCBKR. Compositions and methods of use are provided where the aptamer binds t...
|
|
WO/2017/118355A1 |
Provided in the present application are a nucleotide derivative of a deuterated HCV (Hepatitis C Virus) NS5b inhibitor, or a pharmaceutically acceptable salt, stereoisomer, tauromer inhibitor thereof, and a use thereof in the preparation...
|
|
WO/2017/120508A1 |
Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions ...
|
|
WO/2017/115301A1 |
The present disclosure provides methods for the treatment of breast cancer, including triple negative breast cancer. Said methods comprise the administration of (a) a cationic liposomal formulation comprising a taxane, (b) a non-liposoma...
|
|
WO/2017/109485A1 |
This invention relates to a crystalline form of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate.
|
|
WO/2017/110317A1 |
A nicotinamide mononucleotide derivative represented by general formula (1) or a salt thereof. (In the formula, R1 and R2 each independently represent a hydrogen atom or an acyl group having 3-30 carbon atoms. A hydrocarbon group bonded ...
|
|
WO/2017/104836A1 |
The present invention provides an oligonucleotide production method that includes: (1) a step in which a reaction liquid comprising a phosphite triester body (c) is obtained by condensing, in a nonpolar solvent, a nucleoside, nucleotide,...
|
|
WO/2017/101785A1 |
Disclosed in the present invention are a prodrug comprising a nucleoside analog structure as shown in formula I, a tautomer thereof, a stereisomer thereof, a stereisomer mixture thereof or a pharmaceutically acceptable solvate thereof. A...
|
|
WO/2017/101890A1 |
The present invention relates to a spiroketal derivative having formula (I), a preparation method therefor and an application. R1, R2, R3, R4, X and the A ring are defined in the description. The derivative is an intestine or kidney gluc...
|
|
WO/2017/103109A1 |
The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.
|
|
WO/2017/097973A1 |
The present invention relates to modified nucleosides which are linked to cargo molecules and which can be incorporated by DNA or RNA polymerases in strand synthesis. The present invention also relates to use of such modified nucleosides...
|
|
WO/2017/098252A1 |
The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-p...
|
|
WO/2017/093973A1 |
The present invention provides pure sofosbuvir and a process for the preparation of pure sofosbuvir and its intermediates.
|
|
WO/2017/094011A1 |
The present invention relates to pharmaceutically acceptable salts of conjugates comprising a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by...
|
|
WO/2017/093317A1 |
A method for the mobilization of a transposable element is provided. The method comprises the steps of a) providing an inhibitor of DNA methylation, and/or an inhibitor of transcription, and b) contacting the inhibitor(s) with a cell com...
|
|
WO/2017/096246A1 |
The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.
|
|
WO/2017/090275A1 |
[Problem] To provide a drug that substitutes for injections (5-azacytidine or 2'-deoxy-5-azacytidine) that are clinically used as bone marrow tumor therapeutic drugs, said drug having high stability with respect to metabolic enzyme cytid...
|
|
WO/2017/090264A1 |
[Problem] To provide a drug that substitutes for injections (5-azacytidine or 2'-deoxy-5-azacytidine) that are clinically used as bone marrow tumor therapeutic drugs, said drug having high stability with respect to metabolic enzyme cytid...
|
|
WO/2017/087517A1 |
The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel prodrugs of the invention.
|
|
WO/2017/087887A1 |
This disclosure is related to a method for determining the identity of a nucleotide residue of a single-stranded DNA or RNA, or sequencing DNA or RNA, in a solution using an ion-sensing field effect transistor and reversible nucleotide t...
|
|
WO/2017/086397A1 |
Provided is a novel method for producing an oligonucleotide using a nucleoside or oligonucleotide that is easy to isolate and has high storage stability. A method for producing an oligonucleotide including a step for carrying out H-phosp...
|
|
WO/2017/080973A1 |
The present invention relates to a compound of the general formula (1). wherein A is selected from a group of formula 2. B is selected from a group of formula 3. The compound of formula (1) is suitable for use in a method for treating a ...
|
|
WO/2017/079195A1 |
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the d...
|
|
WO/2017/076266A1 |
The present invention relates to a method for preparing (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-((2-(methylthio)ethyl)a
mino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahyd
rofuran-3,4-diol. Specifically, the present invention relat...
|
|
WO/2017/077552A1 |
A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein.
|
|
WO/2017/079745A1 |
Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
|
|
WO/2017/070464A1 |
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure (I) They are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
|
|
WO/2017/066791A1 |
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...
|
|
WO/2017/066571A1 |
Provided are methods and compositions for treating cancers in patients carrying an IDHl mutation using a combination of an inhibitor of a mutant IDHl enzyme and a DNA demethylating agent.
|
|
WO/2017/066566A1 |
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and an AML induction and consolidation therapy.
|
|
WO/2017/066793A1 |
The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to met...
|
|
WO/2017/066782A1 |
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...
|
|
WO/2017/059249A1 |
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterin...
|
|
WO/2017/058953A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing a nucleic acid.
|
|
WO/2017/053216A2 |
The present invention is directed to 4'-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the proph...
|
|
WO/2017/045583A1 |
Provided is a preparation method of composition rich in compound Sp-1. The method performs isomer separation on a reaction product from a first step, and then performs a two-step chemical synthesis, so as to prepare a composition compris...
|
|
WO/2017/045582A1 |
Provided in the present invention are a novel preparation method of nucleoside phosphoramidate prodrugs and intermediates thereof. In particular, the method is adopted to perform isomer separation on a reaction product from a first step ...
|
|
WO/2017/048147A1 |
The object of the invention is a method of synthesis and purification of a nucleoside and/or a nucleotide being a mono-, di- or triphosphate, wherein a Huisgen' s azide-alkyne cycloaddition reaction is being performed using a compound of...
|
|
WO/2017/045581A1 |
The present invention involves a composition rich in compound 61501b, wherein the compound 61501b has a purity not less than 90% or more. The composition has a significant advantage in preparing high-purity compound Sp-1. In addition, th...
|
